Publications by authors named "Ilya Gubskiy"

Background: Cell therapy using neural progenitor cells (NPCs) is a promising approach for ischemic stroke treatment according to the results of multiple preclinical studies in animal stroke models. In the vast majority of conducted animal studies, the therapeutic efficacy of NPCs was estimated after intracerebral transplantation, while the information of the effectiveness of systemic administration is limited. Nowadays, several clinical trials aimed to estimate the safety and efficacy of NPCs transplantation in stroke patients were also conducted.

View Article and Find Full Text PDF

Methods: We performed a hospital-based prospective cohort study with 1,317 enrolled participants. We compared patients and healthy volunteers according to the main demographic, anthropometric parameters, stroke risk factors, comorbidities, and data of clinical and instrumental examination. In order to balance the study and the control groups for age and sex, the propensity score matching was performed.

View Article and Find Full Text PDF
Article Synopsis
  • Systemic transplantation of mesenchymal stem cells (MSCs) shows potential for treating ischemia-related issues like stroke, though the exact benefits are still unclear.
  • * Researchers developed an MRI method to track how MSCs spread in a live rat brain after a stroke, noting their accumulation in brain vessels shortly after being administered.
  • * Despite the low number of MSCs present in the brain and their short retention time, the treatment led to lasting improvements in neurological function without significantly reducing stroke damage compared to control rats.*
View Article and Find Full Text PDF

Ischemic stroke triggers a whole cascade of pathological changes in the brain, one of which is postischemic inflammation. Since in such cases thrombolytic therapy is often not possible, methods that modulate inflammation and affect microglia become particularly interesting. We synthesized 3-(2-oxo-4-phenylpyrrolidin-1-yl)propane-1-sulfonate calcium(II) (Compound ) and studied its anti-inflammatory activity in in vitro and in vivo models of inflammation and ischemia.

View Article and Find Full Text PDF
Article Synopsis
  • - Researchers explored how well mesenchymal stem cells (MSCs) can be delivered to brain tissue through intra-arterial (IA) transplantation, particularly for treating neurological disorders like stroke.
  • - They studied the relationship between brain blood flow (perfusion) and MSC distribution in both healthy rats and rats with stroke, using advanced MR imaging techniques.
  • - Results showed that brain perfusion partially influences where the MSCs end up after transplantation, but other unknown factors also play a significant role, indicating that more research is needed.
View Article and Find Full Text PDF

Animal model studies and first clinical trials have demonstrated the safety and efficacy of the mesenchymal stem cells' (MSCs) transplantation in stroke. Intra-arterial (IA) administration looks especially promising, since it provides targeted cell delivery to the ischemic brain, is highly effective, and can be safe as long as the infusion is conducted appropriately. However, wider clinical application of the IA MSCs transplantation will only be possible after a better understanding of the mechanism of their therapeutic action is achieved.

View Article and Find Full Text PDF

We performed an in silico, in vitro, and in vivo assessment of a potassium 2-[2-(2-oxo-4-phenylpyrrolidin-1-yl) acetamido]ethanesulfonate (compound ) as a potential prodrug for cognitive function improvement in ischemic brain injury. Using in silico methods, we predicted the pharmacological efficacy and possible safety in rat models. In addition, in silico data showed neuroprotective features of compound , which were further supported by in vitro experiments in a glutamate excitotoxicity-induced model in newborn rat cortical neuron cultures.

View Article and Find Full Text PDF

This study's aim was to investigate CT (computed tomography) pattern dynamics differences within surviving and deceased adult patients with COVID-19, revealing new prognostic factors and reproducing already known data with our patients' cohort: 635 hospitalized patients (55.3% of them were men, 44.7%-women), of which 87.

View Article and Find Full Text PDF

The purpose of our study is to investigate the risk factors of in-hospital mortality among patients who were admitted in an emergency setting to a non-specialized tertiary center during the first peak of coronavirus disease in Moscow in 2020. The Federal Center of Brain and Neurotechnologies of the Federal Medical and Biological Agency of Russia was repurposed for medical care for COVID-19 patients from 6th of April to 16th of June 2020 and admitted the patients who were transported by an ambulance with severe disease. In our study, we analyzed the data of 635 hospitalized patients aged 59.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on addressing key challenges in developing regenerative therapies for spinal cord injuries (SCI) by using directly reprogrammed neural precursor cells (drNPCs) as a potential solution for safe and effective treatment.
  • Researchers performed intraspinal transplantation of drNPCs in seven non-human primates with complete thoracic SCI, comparing the results against a control group receiving a vehicle injection.
  • Findings showed significant recovery in hindlimb function, neurological assessments, and maintained cell multipotency, indicating that drNPC transplantation is a safe and promising approach for enhancing spinal cord function post-injury.
View Article and Find Full Text PDF

Remyelination is a key process enabling post-stroke brain tissue recovery and plasticity. This study aimed to explore the feasibility of demyelination and remyelination monitoring in experimental stroke from the acute to chronic stage using an emerging myelin imaging biomarker, macromolecular proton fraction (MPF). After stroke induction by transient middle cerebral artery occlusion, rats underwent repeated MRI examinations during 85 days after surgery with histological endpoints for the animal subgroups on the 7th, 21st, 56th, and 85th days.

View Article and Find Full Text PDF

Transplantation of various types of stem cells as a possible therapy for stroke has been tested for years, and the results are promising. Recent investigations have shown that the administration of the conditioned media obtained after stem cell cultivation can also be effective in the therapy of the central nervous system pathology (hypothesis of their paracrine action). The aim of this study was to evaluate the therapeutic effects of the conditioned medium of hiPSC-derived glial and neuronal progenitor cells in the rat middle cerebral artery occlusion model of the ischemic stroke.

View Article and Find Full Text PDF
Article Synopsis
  • - Cell therapy, particularly using directly reprogrammed neural precursor cells (drNPC), shows promise for reducing brain damage and improving recovery after a stroke, as tested in a rat model.
  • - The study involved infusing drNPC into the bloodstream of rats 24 hours post-stroke, allowing tracking of these cells via MRI; results indicated that drNPC were present near and within the infarct zone more quickly than the control group of placenta-derived mesenchymal stem cells (pMSC).
  • - Both drNPC and pMSC improved neurological function and reduced stroke effects, but they acted differently in terms of infarct volume and animal survival, hinting at unique therapeutic mechanisms at play, particularly for drNPC.
View Article and Find Full Text PDF

Cell therapy of neurological diseases is gaining momentum. Various types of stem/progenitor cells and their derivatives have shown positive therapeutic results in animal models of neurological disorders and in clinical trials. Each tested cell type proved to have its advantages and flaws and unique cellular and molecular mechanism of action, prompting the idea to test combined transplantation of two or more types of cells (combined cell therapy).

View Article and Find Full Text PDF

The middle cerebral artery occlusion (MCAO) model in rats closely imitates ischemic stroke and is widely used. Existing instrumental methods provide a certain level of MCAO guidance, but monitoring of the MCA-occluding intraluminal filament position and possible complications can be improved. The goal of this study was to develop a MRI-based method of simultaneous control of the filament position, blood flow in the intracranial vessels, and hemorrhagic complications.

View Article and Find Full Text PDF

In vivo tracking of transplanted mesenchymal stem cells (MSCs) migration and homing is vital for understanding the mechanisms of beneficial effects of MSCs transplantation in animal models of diseases and in clinical trials. Transplanted cells can be labeled with superparamagnetic iron oxide (SPIO) particles and visualized in vivo using a number of iron sensitive MRI techniques. However, the applicability of those techniques for SPIO-labeled MSCs tracking in live brain has not been sufficiently investigated.

View Article and Find Full Text PDF

In vivo optical imaging is widely used in preclinical studies. Recently, the application of optical imaging systems for preclinical visualization of gamma-emitting isotopes has become of interest since the evaluation of various organs relies on (99m)Tc-based radiopharmaceuticals (RPs). In vitro radioluminescence of (99m)Tc-based RPs, including pertechnetate, albumin macroaggregates, dimercaptosuccinic acid, phytate colloid, and ethylenediamine tetramethylene phosphonic acid, was studied with IVIS Spectrum CT™ optical imaging system.

View Article and Find Full Text PDF
Article Synopsis
  • * Researchers designed nanogels that carry the chemotherapy drug cisplatin, which are linked to antibodies targeting proteins Cx43 and BSAT1, leading to significant tumor reduction in animal models.
  • * The study showed that these targeted nanogels not only reduced tumor size but also extended survival rates in treated rats, highlighting a promising new approach for glioma treatment.
View Article and Find Full Text PDF